NCT00555880View on ClinicalTrials.gov

Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension

PHASE4CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 8, 2004

Primary Completion Date

March 21, 2005

Study Completion Date

March 21, 2005

Conditions
Hypotension, Orthostatic
Interventions
DRUG

Midodrine hydrochloride

one dose, 10-30mg, given orally

DRUG

Placebo

Placebo

Trial Locations (11)

10029

Mount Sinai Medical Center, New York

27607

Raleigh Neurology Associates, Raleigh

29615

Absher Neurology, PA, Greenville

37212

Vanderbilt University, Nashville

44106

University Hospitals of Cleveland, Cleveland

46805

Fort Wayne Neurological Center, Fort Wayne

48109

University of Michigan, Ann Arbor

55417

Minnesota VA Medical Center, Minneapolis

63139

Forest Park Neurophysiology, St Louis

78229

Diabetes and Glandular Disease research Associates, PA, San Antonio

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors

Lead Sponsor

Shire
All Listed Sponsors
lead

Shire

INDUSTRY

NCT00555880 - Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension | Biotech Hunter | Biotech Hunter